16 December 2021
EMA/CHMP/727702/2021
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion[1] (post authorisation)

Veklury

remdesivir

On 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Veklury. The marketing authorisation holder for this medicinal product is Gilead Sciences Ireland UC.

The CHMP adopted a change to the existing indication as follows:[2]

Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in:

- **adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.**
- adults and adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment). (see section 5.1).

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

[1] Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion
[2] New text in bold

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union